The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Temozolomide in malignant gliomas: current use and future targets
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929 · cited 1×
“Previously, Yung et al. [ 9 , 10] had demonstrated the beneWt of TMZ in patients with WHO grade III astrocytomas and in patients with GBM in Wrst relapse.”
Background
Cited by
DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis
Roos, W. P., & Kaina, B. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.01.007 · Cited by 879
Glioblastoma multiforme: Pathogenesis and treatment
Alifieris, C., & Trafalis, D. T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.005 · Cited by 820
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
Perry, J. R., Bélanger, K., Mason, W. P., Fulton, D., Kavan, P., Easaw, J., Shields, C., Kirby, S., Macdonald, D. R., Eisenstat, D. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5520 · Cited by 384
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
Curtin, N. J., & Szabo, C. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.01.006 · Cited by 369
MGMT Status as a Clinical Biomarker in Glioblastoma
Butler, M., Pongor, L., Su, Y.-T., Xi, L., Raffeld, M., Quezado, M., Trepel, J., Aldape, K., Pommier, Y., & Wu, J. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.02.010 · Cited by 342
Metadata
- Authors
- Villano, J. L., Seery, T. E., & Bressler, L. R.
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2009-06-19
- Volume
- 64
- Issue
- 4
- Pages
- 647-655
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2045594601
- Cited by
- 202
- References
- 3
- FWCI
- 7.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Temozolomide in malignant gliomas: current use and future targets. https://app.cochat.ai/papers/10.1007/s00280-009-1050-5
- The paper
- Villano, J. L., Seery, T. E., & Bressler, L. R. (2009). Temozolomide in malignant gliomas: current use and future targets. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-009-1050-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.